Phase II Study of Cediranib (AZD2171) in Patients With Alveolar Soft Part Sarcoma

Trial Profile

Phase II Study of Cediranib (AZD2171) in Patients With Alveolar Soft Part Sarcoma

Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 08 Aug 2018

At a glance

  • Drugs Cediranib (Primary)
  • Indications Soft tissue sarcoma
  • Focus Therapeutic Use
  • Most Recent Events

    • 07 Jun 2018 Planned primary completion date changed from 31 Jul 2019 to 30 Sep 2018.
    • 05 Jun 2018 Results (n=7) from stage I of the study, presented at the 54th Annual Meeting of the American Society of Clinical Oncology.
    • 04 Apr 2018 Planned End Date changed from 31 Jul 2018 to 31 Jul 2019.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top